Gastrointestinal adverse effects

1 paper

Humans1

Latest

6 in 12 months

Diabetes, Obesity & Metabolism7 Oct

Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy

ReviewMuscle

Advances in Clinical and Experimental Medicine2 Oct

Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics

ReviewIndustry & policy

Diabetes, Obesity & Metabolism15 Sep

Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction

Cureus11 Sep

Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

Systematic review of studies in peopleSGLT2 inhibitors

Frontiers in Endocrinology14 Aug

Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients

Cohort study of 84 peopleGLP-1 receptor agonists

American Journal of Clinical Oncology10 Aug

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Adverse Events in Patients Receiving Platinum Analog-Based Chemotherapy

Cohort study of 200 peopleGLP-1 receptor agonists